These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26402762)

  • 1. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
    Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
    J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
    De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
    J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Cheng YC; Huang YC; Liu HC
    Dement Geriatr Cogn Disord; 2018; 45(5-6):335-352. PubMed ID: 30041236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.
    Whitehair DC; Sherzai A; Emond J; Raman R; Aisen PS; Petersen RC; Fleisher AS;
    Alzheimers Dement; 2010 Sep; 6(5):412-9. PubMed ID: 20813342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
    Rogers SL; Friedhoff LT
    Dementia; 1996; 7(6):293-303. PubMed ID: 8915035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
    Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
    JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.
    Burns A; Yeates A; Akintade L; Del Valle M; Zhang RY; Schwam EM; Perdomo CA
    Drugs Aging; 2008; 25(8):707-14. PubMed ID: 18665662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease.
    Rigaud AS; Traykov L; Latour F; Couderc R; Moulin F; Forette F
    Pharmacogenetics; 2002 Jul; 12(5):415-20. PubMed ID: 12142731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
    Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
    Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
    Choi SH; Kim SY; Na HR; Kim BK; Yang DW; Kwon JC; Park MY
    Dement Geriatr Cogn Disord; 2008; 25(5):445-50. PubMed ID: 18401173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design.
    Pelton GH; Andrews H; Roose SP; Marcus SM; D'Antonio K; Husn H; Petrella JR; Zannas AS; Doraiswamy PM; Devanand DP
    Contemp Clin Trials; 2014 Mar; 37(2):200-8. PubMed ID: 24315979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
    Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
    Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
    Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
    CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donepezil for dementia due to Alzheimer's disease.
    Birks J; Harvey RJ
    Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
    Rogers SL; Friedhoff LT
    Eur Neuropsychopharmacol; 1998 Feb; 8(1):67-75. PubMed ID: 9452942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.